- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06015737
Une étude pour étudier l'efficacité et l'innocuité de l'anifrolumab chez les adultes atteints de lupus érythémateux cutané chronique et/ou subaigu (LAVENDER)
Une étude de phase III multicentrique, randomisée, en double aveugle, contrôlée par placebo, pour évaluer l'efficacité et l'innocuité de l'anifrolumab chez les adultes atteints de lupus érythémateux cutané chronique et/ou subaigu qui sont réfractaires et/ou intolérants au traitement antipaludique
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud, 7500
- Research Site
-
Johannesburg, Afrique du Sud, 2193
- Research Site
-
-
-
-
-
Berlin, Allemagne, 10117
- Research Site
-
Bochum, Allemagne, 44791
- Research Site
-
Dresden, Allemagne, 01307
- Research Site
-
Erlangen, Allemagne, 91054
- Research Site
-
Essen, Allemagne, 45147
- Research Site
-
Freiburg im Breisgau, Allemagne, 79104
- Research Site
-
Hanover, Allemagne, 30625
- Research Site
-
Kiel, Allemagne, 24105
- Research Site
-
Leipzig, Allemagne, 04103
- Research Site
-
Mainz, Allemagne, 55131
- Research Site
-
Marburg, Allemagne, 35043
- Research Site
-
Regensburg, Allemagne, 93053
- Research Site
-
Wuppertal, Allemagne, 42283
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires, Argentine, 1221
- Research Site
-
Córdoba, Argentine, 5000
- Research Site
-
Córdoba, Argentine, X5004BAL
- Research Site
-
Quilmes, Argentine, 1878
- Research Site
-
San Miguel, Argentine, 1663
- Research Site
-
-
-
-
-
Kogarah, Australie, 3168
- Research Site
-
Melbourne, Australie, 3004
- Research Site
-
Mitcham, Australie, 3132
- Research Site
-
Westmead, Australie, 2145
- Research Site
-
Woolloongabba, Australie, 04102
- Research Site
-
-
-
-
-
Belo Horizonte, Brésil, 30150-221
- Research Site
-
Porto Alegre, Brésil, 90035903
- Research Site
-
Rio de Janeiro, Brésil, 22470-220
- Research Site
-
Salvador, Brésil, 40150-150
- Research Site
-
São Paulo, Brésil, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulgarie, 1784
- Research Site
-
Sofia, Bulgarie, 1463
- Research Site
-
Sofia, Bulgarie, 1528
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- Research Site
-
Toronto, Ontario, Canada, M5T 2S8
- Research Site
-
-
-
-
-
Osorno, Chili, 200025
- Research Site
-
Santiago, Chili, 7500571
- Research Site
-
Santiago, Chili, 130021
- Research Site
-
-
-
-
-
Changchun, Chine, 130021
- Research Site
-
Changsha, Chine, 410011
- Research Site
-
Chengdu, Chine, 610021
- Research Site
-
Chongqing, Chine, 400016
- Research Site
-
Dongguan, Chine, 523059
- Research Site
-
Guangzhou, Chine, 510120
- Research Site
-
Heilongjiang, Chine, 150086
- Research Site
-
Jinan, Chine, 250022
- Research Site
-
Shanghai, Chine, 200025
- Research Site
-
Shanghai, Chine, 200443
- Research Site
-
Shenzhen, Chine, 518053
- Research Site
-
Shenzhen, Chine, 518020
- Research Site
-
Shenzhen, Chine, 518052
- Research Site
-
Zhuzhou, Chine, 412007
- Research Site
-
Ürümqi, Chine, CN-830004
- Research Site
-
-
-
-
-
Barranquilla, Colombie, 080020
- Research Site
-
Bogotá, Colombie, 110221
- Research Site
-
-
-
-
-
Seoul, Corée du Sud, 03080
- Research Site
-
Seoul, Corée du Sud, 06591
- Research Site
-
Seoul, Corée du Sud, 06973
- Research Site
-
-
-
-
-
Aarhus, Danemark, 641-8510
- Research Site
-
Copenhagen, Danemark, 2100
- Research Site
-
-
-
-
-
Barcelona, Espagne, 8035
- Research Site
-
Barcelona, Espagne, 08025
- Research Site
-
Castellon, Espagne, 12004
- Research Site
-
Granada, Espagne, 18012
- Research Site
-
L'Hospitalet de Llobregat, Espagne, 08907
- Research Site
-
Las Palmas de Gran Canaria, Espagne, 35010
- Research Site
-
Madrid, Espagne, 28034
- Research Site
-
Madrid, Espagne, 28041
- Research Site
-
Madrid, Espagne, 28040
- Research Site
-
Madrid, Espagne, 28006
- Research Site
-
Majadahonda, Espagne, 28222
- Research Site
-
Salamanca, Espagne, 37007
- Research Site
-
Seville, Espagne, 41014
- Research Site
-
Valencia, Espagne, 46014
- Research Site
-
Valencia, Espagne, 46017
- Research Site
-
Vigo, Espagne, 36200
- Research Site
-
-
-
-
-
Bois-Guillaume, France, 76031
- Research Site
-
Dijon, France, 21000
- Research Site
-
Lyon, France, 69437
- Research Site
-
Montivilliers, France, 76290
- Research Site
-
Nantes, France, 44000
- Research Site
-
Paris, France, 75010
- Research Site
-
Paris, France, 75014
- Research Site
-
Paris, France, 75013
- Research Site
-
Paris, France, 75970
- Research Site
-
Poitiers, France, 86000, FR
- Research Site
-
Toulouse, France, 31059
- Research Site
-
-
-
-
-
Athens, Grèce, 12462
- Research Site
-
Athens, Grèce, 16121
- Research Site
-
-
-
-
-
Brescia, Italie, 25123
- Research Site
-
Cona, Italie, 44124
- Research Site
-
Florence, Italie, 50121
- Research Site
-
Milan, Italie, 20132
- Research Site
-
Naples, Italie, 80138
- Research Site
-
Reggio Emilia, Italie, 42123
- Research Site
-
Roma, Italie, 00144
- Research Site
-
Rome, Italie, 00168
- Research Site
-
-
-
-
-
Chūōku, Japon, 104-8560
- Research Site
-
Fukuoka, Japon, 812-8582
- Research Site
-
Kanazawa, Japon, 920-8641
- Research Site
-
Kita-gun, Japon, 761-0793
- Research Site
-
Nagoya, Japon, 457-8510
- Research Site
-
Nagoya, Japon, 467-8602
- Research Site
-
Wakayama, Japon, 641-8510
- Research Site
-
Yokohama, Japon, 232-0024
- Research Site
-
tabashi City, Japon, 173-8606
- Research Site
-
-
-
-
-
Graz, L'Autriche, 8036
- Research Site
-
Innsbruck, L'Autriche, 6020
- Research Site
-
Linz, L'Autriche, 4020
- Research Site
-
Vienna, L'Autriche, 1130
- Research Site
-
-
-
-
-
Braga, Le Portugal, 4710-243
- Research Site
-
Lisbon, Le Portugal, 1649-035
- Research Site
-
Porto, Le Portugal, 4099-001
- Research Site
-
-
-
-
-
Guadalajara, Mexique, 44340
- Research Site
-
Guadalajara, Mexique, 44610
- Research Site
-
Mexico City, Mexique, 07760
- Research Site
-
Veracruz, Mexique, 91910
- Research Site
-
-
-
-
-
Papatoetoe, Nouvelle-Zélande, 2025
- Research Site
-
-
-
-
-
Breda, Pays-Bas, 4818 CK
- Research Site
-
Rotterdam, Pays-Bas, 3015 GD
- Research Site
-
-
-
-
-
Iloilo City, Philippines, 5000
- Research Site
-
Lipa, Philippines, 4217
- Research Site
-
Manila, Philippines, 1000
- Research Site
-
-
-
-
-
Katowice, Pologne, 40-851
- Research Site
-
Kielce, Pologne, 25-316
- Research Site
-
Ossy, Pologne, 40-027
- Research Site
-
Rzeszów, Pologne, 35-055
- Research Site
-
Warsaw, Pologne, 02-637
- Research Site
-
-
-
-
-
Bucharest, Roumanie, 020125
- Research Site
-
Iași, Roumanie, 700291
- Research Site
-
-
-
-
-
Cambridge, Royaume-Uni, CB2 0QQ
- Research Site
-
Leeds, Royaume-Uni, LS2 9JT
- Research Site
-
London, Royaume-Uni, NW1 2PG
- Research Site
-
London, Royaume-Uni, SE5 9RS
- Research Site
-
London, Royaume-Uni, SE1 7EH
- Research Site
-
London, Royaume-Uni, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Royaume-Uni, NE1 4LP
- Research Site
-
-
-
-
-
Belgrade, Serbie, 11000
- Research Site
-
Kragujevac, Serbie, 34000
- Research Site
-
-
-
-
-
Košice, Slovaquie, 04001
- Research Site
-
Piešťany, Slovaquie, 92101
- Research Site
-
-
-
-
-
Kaohsiung City, Taïwan, 83301
- Research Site
-
Taichung, Taïwan, 404
- Research Site
-
Taipei, Taïwan, 10449
- Research Site
-
-
-
-
-
Bangkok, Thaïlande, 10330
- Research Site
-
Bangkok, Thaïlande, 10700
- Research Site
-
Hat Yai, Thaïlande, 90110
- Research Site
-
Khlong Luang, Thaïlande, 12120
- Research Site
-
Khon Kaen, Thaïlande, 40002
- Research Site
-
-
-
-
-
Cordaleo, Turquie (Türkiye), 35575
- Research Site
-
Istanbul, Turquie (Türkiye), 34098
- Research Site
-
Kayseri, Turquie (Türkiye), 38039
- Research Site
-
Samsun, Turquie (Türkiye), 55270
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85028
- Research Site
-
-
California
-
Covina, California, États-Unis, 91722
- Research Site
-
La Jolla, California, États-Unis, 92037
- Research Site
-
Los Angeles, California, États-Unis, 90045
- Research Site
-
Los Angeles, California, États-Unis, 90089
- Research Site
-
Orange, California, États-Unis, 92868
- Research Site
-
San Francisco, California, États-Unis, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33309
- Research Site
-
Miami, Florida, États-Unis, 33174
- Research Site
-
Plantation, Florida, États-Unis, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Research Site
-
Chicago, Illinois, États-Unis, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Research Site
-
Boston, Massachusetts, États-Unis, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Research Site
-
Bloomfield Hills, Michigan, États-Unis, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198-5885
- Research Site
-
-
New York
-
New York, New York, États-Unis, 10028
- Research Site
-
Rochester, New York, États-Unis, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28207
- Research Site
-
Statesville, North Carolina, États-Unis, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, États-Unis, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, États-Unis, 22903
- Research Site
-
Roanoke, Virginia, États-Unis, 24016
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Comparateur placebo: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Délai: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from baseline in total CLASI-A score
Délai: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Délai: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Délai: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Délai: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Délai: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Délai: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Délai: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Délai: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Délai: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Délai: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Délai: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Délai: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Délai: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Délai: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Délai: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with adverse events
Délai: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- D346BC00001
- 2021-003698-70 (Numéro EudraCT)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .